Skip to content
2000
Volume 25, Issue 22
  • ISSN: 1389-5575
  • E-ISSN: 1875-5607

Abstract

Chronic Obstructive Pulmonary Disease (COPD) is a respiratory condition defined by persistent bronchitis, emphysema, and structural remodelling. The number of cases has risen globally; however, limited viable remedies exist. It is linked to airway blockage, oxidative stress, chronic conditions, inflammation, excessive mucus production, and increased autophagy and cellular senescence. Beta-2 adrenergic receptors (β-ARs) play a significant role in both the aetiology and management of COPD. Beta-2 agonists (particularly long-acting beta-agonists, or LABAs) are preferable in COPD therapy due to their powerful bronchodilation, rapid onset, prolonged duration, and potential synergistic effects with other medications. They are well-tolerated and effective in improving the quality of life and reducing exacerbations, making them an essential component of COPD treatment. Currently, there are fewer bronchodilators that have been found to be effective. This leads to an exploration of novel, long-acting, and ultra-long-acting drugs for the management of COPD.

This article provides an extensive overview of natural β agonists. The current study emphasizes the rational development of lead candidates, including trantinterol, isopropyl, tert-butyl, and heterocyclic ring 2-amino-2-phenylethanol derivatives, 8-(2-amino-1-hydroxyethyl)-6-hydroxy-1,4-benzoxazine-3(4)-one derivatives (non-substituted, methyl-substituted, dimethyl-substituted), 5-(2-amino-1-hydroxyethyl)-8-hydroxyquinolin-2(1)-one analogues, indacaterol analogues, saligenin antedrugs, and saligenin alkoxyalkylphenyl sulfonamide derivatives, accompanied by molecular docking studies. This paper also highlights numerous structure-activity relationship investigations and various novel β agonists currently in clinical trials and patents. The present review will significantly aid in fostering the research of COPD.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/mrmc/10.2174/0113895575398230251001073434
2025-10-21
2026-02-25

  • From This Site

    /content/journals/mrmc/10.2174/0113895575398230251001073434
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. DevineJ.F. Chronic obstructive pulmonary disease: An overview.Am. Health Drug Benefits2008173442 25126252
     [Google Scholar]
  2. MurrayC.J.L. LopezA.D. Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study.Lancet199734990641498150410.1016/S0140‑6736(96)07492‑2 9167458
     [Google Scholar]
  3. ManninoD.M. COPD: Epidemiology, prevalence, morbidity and mortality, and disease heterogeneity.Chest20021215121S126S10.1378/chest.121.5_suppl.121S 12010839
     [Google Scholar]
  4. BarnesP.J. Small airways in COPD.N. Engl. J. Med.2004350262635263710.1056/NEJMp048102 15215476
     [Google Scholar]
  5. StollerJ.K. FromerL. BrantlyM. StocksJ. StrangeC. Primary care diagnosis of alpha-1 antitrypsin deficiency: Issues and opportunities.Cleve. Clin. J. Med.2007741286987410.3949/ccjm.74.12.869 18183837
     [Google Scholar]
  6. AzadM.B. ConeysJ.G. KozyrskyjA.L. FieldC.J. RamseyC.D. BeckerA.B. FriesenC. Abou-SettaA.M. ZarychanskiR. Probiotic supplementation during pregnancy or infancy for the prevention of asthma and wheeze: Systematic review and metaanalysis.BMJ2013347dec04 12f6471f647110.1136/bmj.f6471 24304677
     [Google Scholar]
  7. FitzgeraldM. FoxJ. Emerging trends in the therapy of COPD: Bronchodilators as mono- and combination therapies.Drug Discov. Today20071211-1247247810.1016/j.drudis.2007.04.003 17532532
     [Google Scholar]
  8. ViegiG. PistelliF. SherrillD.L. MaioS. BaldacciS. CarrozziL. Definition, epidemiology and natural history of COPD.Eur. Respir. J.2007305993101310.1183/09031936.00082507 17978157
     [Google Scholar]
  9. BarnesP.J. Mediators of chronic obstructive pulmonary disease.Pharmacol. Rev.200456451554810.1124/pr.56.4.2 15602009
     [Google Scholar]
  10. BarnesP.J. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease.J. Allergy Clin. Immunol.20161381162710.1016/j.jaci.2016.05.011 27373322
     [Google Scholar]
  11. O’DonnellD.E. LavenezianaP. WebbK. NederJ.A. Chronic obstructive pulmonary disease: Clinical integrative physiology.Clin. Chest Med.2014351516910.1016/j.ccm.2013.09.008 24507837
     [Google Scholar]
  12. JeongJ.S. KimJ.S. YouY.S. YeomS.W. LeeY.C. COPD is a risk factor for COVID-19, but does not confer increased severity of the disease.Respir. Med.202118910664010.1016/j.rmed.2021.106640 34627008
     [Google Scholar]
  13. KimY. LeeH. LeeS-K. YangB. ChoiH. ParkD.W. ParkT.S. MoonJ-Y. KimT-H. SohnJ.W. YoonH.J. KimS-H. Chronic obstructive pulmonary disease is associated with a more symptomatic burden and severe presentation of COVID-19: A korean national covid-19 cohort study.Tohoku J. Exp. Med.2022256320921410.1620/tjem.256.209 35314528
     [Google Scholar]
  14. JohansenM.D. MahbubR.M. IdreesS. NguyenD.H. MiemczykS. PathinayakeP. NicholK. HansbroN.G. GearingL.J. HertzogP.J. Gallego-OrtegaD. BrittonW.J. SaundersB.M. WarkP.A. FaizA. HansbroP.M. Increased SARS-CoV-2 infection, protease, and inflammatory responses in chronic obstructive pulmonary disease primary bronchial epithelial cells defined with single-cell RNA sequencing.Am. J. Respir. Crit. Care Med.2022206671272910.1164/rccm.202108‑1901OC 35549656
     [Google Scholar]
  15. RabbaniG. Shariful IslamS.M. RahmanM.A. AminN. MarzanB. RobinR.C. AlifS.M. Pre-existing COPD is associated with an increased risk of mortality and severity in COVID-19: A rapid systematic review and meta-analysis.Expert Rev. Respir. Med.202115570571610.1080/17476348.2021.1866547 33334189
     [Google Scholar]
  16. AlqahtaniJ.S. OyeladeT. AldhahirA.M. AlghamdiS.M. AlmehmadiM. AlqahtaniA.S. QuaderiS. MandalS. HurstJ.R. Prevalence, severity and mortality associated with COPD and smoking in patients with COVID-19: A rapid systematic review and meta-analysis.PLoS One2020155e023314710.1371/journal.pone.0233147 32392262
     [Google Scholar]
  17. MezaD. KhuderB. BaileyJ.I. RosenbergS.R. KalhanR. ReyfmanP.A. Mortality from COVID-19 in patients with COPD: A US study in the N3C data enclave.Int. J. Chron. Obstruct. Pulmon. Dis.2021162323232610.2147/COPD.S318000 34413640
     [Google Scholar]
  18. BollmeierS.G. HartmannA.P. Management of chronic obstructive pulmonary disease: A review focusing on exacerbations.Am. J. Health Syst. Pharm.202077425926810.1093/ajhp/zxz306 31930287
     [Google Scholar]
  19. ZhongN. WangC. ZhouX. ZhangN. HumphriesM. WangL. ThachC. PatalanoF. BanerjiD. ZhongN.S. LANTERN: A randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.Int. J. Chron. Obstruct. Pulmon. Dis.2015101015102610.2147/COPD.S84436 26082625
     [Google Scholar]
  20. JansonC. WiklundF. TelgG. StratelisG. SandelowskyH. High use of short-acting β2-agonists in COPD is associated with an increased risk of exacerbations and mortality.ERJ Open Res.202393007220202210.1183/23120541.00722‑2022 37342089
     [Google Scholar]
  21. MiravitllesM. KawayamaT. DreherM. LABA/LAMA as first-line therapy for COPD: A summary of the evidence and guideline recommendations.J. Clin. Med.20221122662310.3390/jcm11226623 36431099
     [Google Scholar]
  22. LipsonD.A. BarnacleH. BirkR. BrealeyN. LocantoreN. LomasD.A. Ludwig-SengpielA. MohindraR. TabbererM. ZhuC.Q. PascoeS.J. FULFIL trial: Once-daily triple therapy for patients with chronic obstructive pulmonary disease.Am. J. Respir. Crit. Care Med.2017196443844610.1164/rccm.201703‑0449OC 28375647
     [Google Scholar]
  23. BurkesR.M. PanosR.J. Ultra long-acting β-agonists in chronic obstructive pulmonary disease.J. Exp. Pharmacol.20201258960210.2147/JEP.S259328 33364854
     [Google Scholar]
  24. CydulkaR. DavisonR. GrammerL. ParkerM. MathewsJ. The use of epinephrine in the treatment of older adult asthmatics.Ann. Emerg. Med.198817432232610.1016/S0196‑0644(88)80772‑8 3354935
     [Google Scholar]
  25. SteinJ.F. WiddicombeJ.G. Nervously-mediated changes in tracheal volume on medullary stimulation of dogs.Respir. Physiol.19709334835510.1016/0034‑5687(70)90091‑5 5425198
     [Google Scholar]
  26. ChenK.K. SchmidtC.F. The action of ephedrine, the active principle of the chinese drug ma huang.J. Pharmacol. Exp. Ther.192424533935710.1016/S0022‑3565(25)05630‑7
     [Google Scholar]
  27. TrendelenburgU. de la SierraB.G.A. MuskusA. Modification by reserpine of the response of the atrial pacemaker to sympathomimetic amines.J. Pharmacol. Exp. Ther.1963141330130910.1016/S0022‑3565(25)26615‑0 14064191
     [Google Scholar]
  28. BiermanC.W. Adrenergic drugs.Clin. Rev. Allergy1983118710410.1007/BF02991319 6142760
     [Google Scholar]
  29. SipkemaD. FranssenM.C.R. OsingaR. TramperJ. WijffelsR.H. Marine sponges as pharmacy.Mar. Biotechnol.20057314216210.1007/s10126‑004‑0405‑5 15776313
     [Google Scholar]
  30. SuzukiH. UenoA. TakeiM. SindoK. MiuraT. SakakibaraM. HigaT. FukamachiH. Tracheal relaxing effects and β2 adrenoceptor selectivity of S1319, a novel sponge‐derived bronchodilator agent, in isolated guinea‐pig tissues.Br. J. Pharmacol.1999128371672010.1038/sj.bjp.0702839 10516653
     [Google Scholar]
  31. SuzukiH. UenoA. TakeiM. ShindoK. HigaT. FukamachiH. The effects of S1319, a novel marine sponge-derived β2-adrenoceptor agonist, on IgE-mediated activation of human cultured mast cells.Inflamm. Res.2000492869410.1007/s000110050563 10738947
     [Google Scholar]
  32. WaldeckB. β-Adrenoceptor agonists and asthma—100 years of development.Eur. J. Pharmacol.20024451-211210.1016/S0014‑2999(02)01728‑4 12065188
     [Google Scholar]
  33. XingG. LiZ. ZhiZ. YiC. ZhangR. YangH. ZhangY. LinB. LiuY. PanL. ChengM. Discovery and identification of novel 5-hydroxy-4 H -benzo[1,4]oxazin-3-one derivatives as potent β 2 -adrenoceptor agonists through structure-based design, synthesis, and biological evaluation.J. Med. Chem.20246742986300310.1021/acs.jmedchem.3c02074 38347756
     [Google Scholar]
  34. DiderichsenP.M. CoxE. MartinS.W. CletonA. RibbingJ. Predicted heart rate effect of inhaled PF‐00610355, a long acting β‐adrenoceptor agonist, in volunteers and patients with chronic obstructive pulmonary disease.Br. J. Clin. Pharmacol.201376575276210.1111/bcp.12080 23323609
     [Google Scholar]
  35. BonnertR.V. BrownR.C. ChapmanD. CheshireD.R. DixonJ. InceF. KinchinE.C. LyonsA.J. DavisA.M. HallamC. HarperS.T. UnittJ.F. DougallI.G. JacksonD.M. McKechnieK. YoungA. SimpsonW.T. Dual D2-receptor and β2-adrenoceptor agonists for the treatment of airway diseases. 1. Discovery and biological evaluation of some 7-(2-aminoethyl)-4-hydroxybenzothiazol-2(3 H)-one analogues.J. Med. Chem.199841254915491710.1021/jm980421f 9836607
     [Google Scholar]
  36. JacobsenJ.R. AggenJ.B. ChurchT.J. KleinU. PfeifferJ.W. Pulido-RiosT.M. ThomasG.R. YuC. MoranE.J. Multivalent design of long-acting β2-adrenoceptor agonists incorporating biarylamines.Bioorg. Med. Chem. Lett.201424122625263010.1016/j.bmcl.2014.04.069 24813741
     [Google Scholar]
  37. McKinnellR.M. KleinU. LinsellM.S. MoranE.J. NodwellM.B. PfeifferJ.W. ThomasG.R. YuC. JacobsenJ.R. Discovery of TD-4306, a long-acting β2-agonist for the treatment of asthma and COPD.Bioorg. Med. Chem. Lett.201424132871287610.1016/j.bmcl.2014.04.095 24835980
     [Google Scholar]
  38. ApariciM. CarcasonaC. RamosI. MonteroJ.L. OtalR. OrtizJ.L. CortijoJ. PuigC. VilellaD. De AlbaJ. DoeC. GavaldàA. MiralpeixM. Pharmacological profile of AZD8871 (LAS191351), a novel inhaled dual M3 receptor antagonist/β2 -adrenoceptor agonist molecule with long-lasting effects and favorable safety profile.J. Pharmacol. Exp. Ther.2019370112713610.1124/jpet.118.255620 31085697
     [Google Scholar]
  39. JacobsenJ.R. ChoiS.K. CombsJ. FournierE.J.L. KleinU. PfeifferJ.W. ThomasG.R. YuC. MoranE.J. A multivalent approach to the discovery of long-acting β2-adrenoceptor agonists for the treatment of asthma and COPD.Bioorg. Med. Chem. Lett.20122221213121810.1016/j.bmcl.2011.11.072 22178551
     [Google Scholar]
  40. GanL.L. WangM.W. ChengM.S. PanL. Trachea relaxing effects and beta2-selectivity of SPFF, a newly developed bronchodilating agent, in guinea pigs and rabbits.Biol. Pharm. Bull.200326332332810.1248/bpb.26.323 12612441
     [Google Scholar]
  41. LiY. JinH. LiQ. ShiL. MaoY. ZhaoL. The role of RNA methylation in tumor immunity and its potential in immunotherapy.Mol. Cancer202423113010.1186/s12943‑024‑02041‑8 38902779
     [Google Scholar]
  42. BenoyC.J. El-FellahM.S. SchneiderR. WadeO.L. Tolerance to sympathomimetic bronchodilators in guinea‐pig isolated lungs following chronic administration in vivo.Br. J. Pharmacol.197555454755410.1111/j.1476‑5381.1975.tb07431.x 1212562
     [Google Scholar]
  43. SchaumannO. Über Oxy-Ephedrine.Naunyn Schmiedebergs Arch. Pharmacol.1931160212717610.1007/BF01863747
     [Google Scholar]
  44. BielJ.H. SchwarzE.G. SprengelerE.P. LeiserH.A. FriedmanH.L. Bronchodilators, N-substituted derivatives of 1-(3′,4′-dihydroxyphenyl)-2-aminoethanol (Arterenol).J. Am. Chem. Soc.195476123149315310.1021/ja01641a010
     [Google Scholar]
  45. MooreP.F. ConstantineJ.W. BarthW.E. Pirbuterol, a selecttve beta2 adrenergic bronchodilator.J. Pharmacol. Exp. Ther.1978207241041810.1016/S0022‑3565(25)31437‑0 712629
     [Google Scholar]
  46. ChiarinoD. FantucciM. CarenziA. Della BellaD. FrigeniV. SalaR. New isoxazole derivatives with a potent and selective beta 2-adrenergic activity.Farmaco, Sci.1986416440453 2874994
     [Google Scholar]
  47. HidakaH. InagakiM. KawamotoS. SasakiY. Isoquinolinesulfonamides, novel and potent inhibitors of cyclic nucleotide-dependent protein kinase and protein kinase C.Biochemistry198423215036504110.1021/bi00316a032 6238627
     [Google Scholar]
  48. JohanssonL.H. PerssonH. β2-Adrenoceptors in guinea-pig atria.J. Pharm. Pharmacol.1983351280480710.1111/j.2042‑7158.1983.tb02900.x 6141243
     [Google Scholar]
  49. CroweM.J. CounihanH.E. O’MalleyK. A comparative study of a new selective beta 2‐adrenoceptor agonist, procaterol and salbutamol in asthma.Br. J. Clin. Pharmacol.198519678779110.1111/j.1365‑2125.1985.tb02715.x 2862893
     [Google Scholar]
  50. XingG. PanL. YiC. LiX. GeX. ZhaoY. LiuY. LiJ. WooA. LinB. ZhangY. ChengM. Design, synthesis and biological evaluation of 5-(2-amino-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one derivatives as potent β2 -adrenoceptor agonists.Bioorg. Med. Chem.201927122306231410.1016/j.bmc.2018.10.043 30392952
     [Google Scholar]
  51. YiC. XingG. WangS. LiX. LiuY. LiJ. LinB. WooA.Y.H. ZhangY. PanL. ChengM. Design, synthesis and biological evaluation of 8-(2-amino-1-hydroxyethyl)-6-hydroxy-1,4-benzoxazine-3(4H)-one derivatives as potent β2-adrenoceptor agonists.Bioorg. Med. Chem.202028111517810.1016/j.bmc.2019.115178 31753798
     [Google Scholar]
  52. XingG. ZhiZ. YiC. ZouJ. JingX. Yiu-Ho WooA. LinB. PanL. ZhangY. ChengM. 8-Hydroxyquinolin-2(1H)-one analogues as potential β2-agonists: Design, synthesis and activity study.Eur. J. Med. Chem.202122411369710.1016/j.ejmech.2021.113697 34273662
     [Google Scholar]
  53. MllliganG. SvobodaP. BrownC.M. Why are there so many adrenoceptor subtypes?Biochem. Pharmacol.19944861059107110.1016/0006‑2952(94)90141‑4 7945399
     [Google Scholar]
  54. TaylorM.R.G. Pharmacogenetics of the human beta-adrenergic receptors.Pharmacogenomics J.200771293710.1038/sj.tpj.6500393 16636683
     [Google Scholar]
  55. CazzolaM. PageC.P. RoglianiP. MateraM.G. β2-agonist therapy in lung disease.Am. J. Respir. Crit. Care Med.2013187769069610.1164/rccm.201209‑1739PP 23348973
     [Google Scholar]
  56. MandalS. BhuyanS. JanaS. HossainJ. ChhetriK. RoyB.G. Efficient visible light mediated synthesis of quinolin-2(1 H)-ones from quinoline N -oxides.Green Chem.202123145049505510.1039/D1GC01460A
     [Google Scholar]
  57. JozwiakK. WooA.Y.H. TangaM.J. TollL. JimenezL. KozocasJ.A. PlazinskaA. XiaoR.P. WainerI.W. Comparative molecular field analysis of fenoterol derivatives: A platform towards highly selective and effective β2-adrenergic receptor agonists.Bioorg. Med. Chem.201018272873610.1016/j.bmc.2009.11.062 20036561
     [Google Scholar]
  58. TrofastJ. Steric aspects of agonism and antagonism at B‐adrenoceptors: Synthesis of and pharmacological experiments with the enantiomers of formoterol and their diastereomers.Chirality1991344345010.1002/chir.530030606 1687501
     [Google Scholar]
  59. HoenkeC. BouyssouT. TautermannC.S. RudolfK. SchnappA. KonetzkiI. Use of 5-hydroxy-4 H -benzo[1,4]oxazin-3-ones as β 2 -adrenoceptor agonists.Bioorg. Med. Chem. Lett.200919236640664410.1016/j.bmcl.2009.10.013 19875286
     [Google Scholar]
  60. BouyssouT. HoenkeC. RudolfK. LustenbergerP. PestelS. SiegerP. LotzR. HeineC. BüttnerF.H. SchnappA. KonetzkiI. Discovery of olodaterol, a novel inhaled β 2 -adrenoceptor agonist with a 24 h bronchodilatory efficacy.Bioorg. Med. Chem. Lett.20102041410141410.1016/j.bmcl.2009.12.087 20096576
     [Google Scholar]
  61. KurtS. AntonM. Ernst-OttoR. ArminF. (1-Hydroxy-2-amino-alkyl) substituted benzoxazinones and benzoxazolinones.U.S. Patent 4,460,5811984
  62. GeX. MoY. XingG. JiL. ZhaoH. ChenJ. HeB. ChenX. XingR. LiX. ZhaoY. LiJ. YanH. WooA.Y.H. ZhangY. LinB. PanL. ChengM. Synthesis, biological evaluation and molecular modeling of 2-amino-2-phenylethanol derivatives as novel β2-adrenoceptor agonists.Bioorg. Chem.20187915516210.1016/j.bioorg.2018.04.017 29751321
     [Google Scholar]
  63. BaurF. BeattieD. BeerD. BentleyD. BradleyM. BruceI. CharltonS.J. CuenoudB. ErnstR. FairhurstR.A. FallerB. FarrD. KellerT. FozardJ.R. FullertonJ. GarmanS. HattoJ. HaydenC. HeH. HowesC. JanusD. JiangZ. LewisC. Loeuillet-RitzlerF. MoserH. ReillyJ. StewardA. SykesD. TedaldiL. TrifilieffA. TweedM. WatsonS. WisslerE. WyssD. The identification of indacaterol as an ultralong-acting inhaled β 2 -adrenoceptor agonist.J. Med. Chem.20105393675368410.1021/jm100068m 20402514
     [Google Scholar]
  64. BeattieD. BeerD. BradleyM.E. BruceI. CharltonS.J. CuenoudB.M. FairhurstR.A. FarrD. FozardJ.R. JanusD. RosethorneE.M. SandhamD.A. SykesD.A. TrifilieffA. TurnerK.L. WisslerE. An investigation into the structure–activity relationships associated with the systematic modification of the β2-adrenoceptor agonist indacaterol.Bioorg. Med. Chem. Lett.201222196280628510.1016/j.bmcl.2012.07.096 22932315
     [Google Scholar]
  65. BennettJ.A. HarrisonT.W. TattersfieldA.E. The contribution of the swallowed fraction of an inhaled dose of salmeterol to it systemic effects.Eur. Respir. J.199913244544810.1183/09031936.99.13244599 10065696
     [Google Scholar]
  66. RosethorneE.M. TurnerR.J. FairhurstR.A. CharltonS.J. Efficacy is a contributing factor to the clinical onset of bronchodilation of inhaled β2-adrenoceptor agonists.Naunyn Schmiedebergs Arch. Pharmacol.2010382325526310.1007/s00210‑010‑0533‑6 20694793
     [Google Scholar]
  67. MancheeG.R. BarrowA. KulkarniS. PalmerE. OxfordJ. ColthupP.V. MaconochieJ.G. TarbitM.H. Disposition of salmeterol xinafoate in laboratory animals and humans.Drug Metab. Dispos.19932161022102810.1016/S0090‑9556(25)08195‑4 7905380
     [Google Scholar]
  68. MancheeG.R. EddershawP.J. RanshawL.E. HerriottD. ParkG.R. BaylissM.K. TarbitM.H. The aliphatic oxidation of salmeterol to alpha-hydroxysalmeterol in human liver microsomes is catalyzed by CYP3A.Drug Metab. Dispos.1996245555559 8723736
     [Google Scholar]
  69. ProcopiouP.A. BarrettV.J. BevanN.J. BiggadikeK. ButchersP.R. CoeD.M. ConroyR. EdneyD.D. FieldR.N. FordA.J. GuntripS.B. LookerB.E. McLayI.M. MonteithM.J. MorrisonV.S. MutchP.J. RichardsS.A. SasseR. SmithC.E. Synthesis and structure-activity relationships of long-acting β 2 adrenergic receptor agonists incorporating arylsulfonamide groups.J. Med. Chem.20095282280228810.1021/jm801016j 19317397
     [Google Scholar]
  70. MateraM.G. PageC.P. CalzettaL. RoglianiP. CazzolaM. Pharmacology and therapeutics of bronchodilators revisited.Pharmacol. Rev.202072121825210.1124/pr.119.018150 31848208
     [Google Scholar]
  71. ApariciM. Gómez-AngelatsM. VilellaD. OtalR. CarcasonaC. ViñalsM. RamosI. GavaldàA. De AlbaJ. GrasJ. CortijoJ. MorcilloE. PuigC. RyderH. BeletaJ. MiralpeixM. Pharmacological characterization of abediterol, a novel inhaled β(2)-adrenoceptor agonist with long duration of action and a favorable safety profile in preclinical models.J. Pharmacol. Exp. Ther.2012342249750910.1124/jpet.112.193284 22588259
     [Google Scholar]
  72. CrimC. GotfriedM. SpangenthalS. WatkinsM. EmmettA. CrawfordC. BaidooC. Castro-SantamariaR. A randomized, controlled, repeat-dose study of batefenterol/fluticasone furoate compared with placebo in the treatment of COPD.BMC Pulm. Med.202020111910.1186/s12890‑020‑1153‑7 32366249
     [Google Scholar]
  73. Lo BelloF. HansbroP.M. DonovanC. CoppolinoI. MumbyS. AdcockI.M. CaramoriG. New drugs under development for COPD.Expert Opin. Emerg. Drugs202025441943110.1080/14728214.2020.1819982 32882146
     [Google Scholar]
  74. GlossopP.A. LaneC.A.L. PriceD.A. BunnageM.E. LewthwaiteR.A. JamesK. BrownA.D. YeadonM. Perros-HuguetC. TrevethickM.A. ClarkeN.P. WebsterR. JonesR.M. BurrowsJ.L. FeederN. TaylorS.C.J. SpenceF.J. Inhalation by design: Novel ultra-long-acting β(2)-adrenoreceptor agonists for inhaled once-daily treatment of asthma and chronic obstructive pulmonary disease that utilize a sulfonamide agonist headgroup.J. Med. Chem.201053186640665210.1021/jm1005989 20804199
     [Google Scholar]
  75. MickleTravis KrishnanSuma BishopBarney LauderbackChristopher MoncriefJames Scott OberlenderRobert PiccarielloThomas PaulBernhard J. VerbickyChristopher A. Abuse-resistant amphetamine prodrugs.U.S. Patent 7.659,253 B22010
     [Google Scholar]
  76. ApariciM. CarcasonaC. RamosI. MonteroJ.L. OrtizJ.L. CortijoJ. PuigC. VilellaD. DoeC. GavaldàA. MiralpeixM. Pharmacological preclinical characterization of LAS190792, a novel inhaled bifunctional muscarinic receptor antagonist/β2-adrenoceptor agonist (MABA) molecule.Pulm. Pharmacol. Ther.20174611010.1016/j.pupt.2017.07.003 28729041
     [Google Scholar]
  77. MilaraJ. ContrerasS. de DiegoA. CalbetM. ApariciM. MorcilloE. MiralpeixM. CortijoJ. In vitro anti-inflammatory effects of AZD8999, a novel bifunctional muscarinic acetylcholine receptor antagonist/β2-adrenoceptor agonist (MABA) compound in neutrophils from COPD patients.PLoS One2019141e021018810.1371/journal.pone.0210188 30608978
     [Google Scholar]
  78. Include the corrected Reference as: Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention (2020 update).Available from: https://ginasthma.org/wp-content/uploads/2020/04/GINA-2020-full-report_-final-_wms.pdf
  79. LaurentC. Phenethanolamine derivatives as beta-2 adrenoreceptor agonists.U.S. Patent EP001577291A12005
     [Google Scholar]
  80. Global initiative for chronic obstructive lung.2017Available from: https://goldcopd.org/
  81. BarnesP.J. Immunology of asthma and chronic obstructive pulmonary disease.Nat. Rev. Immunol.20088318319210.1038/nri2254 18274560
     [Google Scholar]
  82. Asthma COPD and Asthma - COPD overlap syndrome chromeextension.2016Available from: https://goldcopd.org/wp-content/uploads/2016/04/GOLD_ACOS_2015.pdf
  83. CaramoriG. CasolariP. BarczykA. DurhamA.L. Di StefanoA. AdcockI. COPD immunopathology.Semin. Immunopathol.201638449751510.1007/s00281‑016‑0561‑5 27178410
     [Google Scholar]
  84. BusseW.W. ShahS.R. SomervilleL. ParasuramanB. MartinP. GoldmanM. Comparison of adjustable- and fixed-dose budesonide/formoterol pressurized metered-dose inhaler and fixeddose fluticasone propionate/salmeterol dry powder inhaler in asthma patients.J. Allergy Clin. Immunol.200812161407-1414.e6, 1414.e1-1414.e6.10.1016/j.jaci.2008.03.019 18455221
     [Google Scholar]
  85. WelteT. Optimising treatment for COPD - New strategies for combination therapy.Int. J. Clin. Pract.20096381136114910.1111/j.1742‑1241.2009.02139.x 19624783
     [Google Scholar]
  86. RanaN. GroverP. SinghH. Recent developments and future perspectives of purine derivatives as a promising scaffold in drug discovery.Curr. Top. Med. Chem.202424654157910.2174/0115680266290152240110074034 38288806
     [Google Scholar]
/content/journals/mrmc/10.2174/0113895575398230251001073434
Loading
COPD Treatment with Beta 2-Adrenoreceptor Agonists: Medicinal Perspectives and Recent Advances
Mini Rev Med Chem 25, 1696 (2025); https://doi.org/10.2174/0113895575398230251001073434
/content/journals/mrmc/10.2174/0113895575398230251001073434
/content/journals/mrmc/10.2174/0113895575398230251001073434
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): Beta-2 adrenergic receptors; bronchodilators; COPD; natural β2 agonists; novel β2 agonists; structure-activity relationship investigations

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test